CoChat

Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication

Benn, Marianne, Watts, Gerald F., Tybjaerg-Hansen, Anne, Nordestgaard, Børge G. · 2012 · The Journal of Clinical Endocrinology & Metabolism

The DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.

Abstract

Context: The diagnosis of familial hypercholesterolemia (FH) can be made using the Dutch Lipid Clinic Network criteria. This employs the personal and family history of premature coronary artery disease and hypercholesterolemia and the presence of a pathogenic mutation in the low-density lipoprotein receptor (LDLR) and apolipoprotein B (APOB) genes. Objective: We employed this tool to investigate the prevalence of FH and the associations between FH and coronary artery disease and cholesterol-lowering medication in the Copenhagen General Population Study. Setting: The study was of an unselected, community-based population comprising 69,016 participants. Main Outcome Measures: FH (definite/probable) was defined as a Dutch Lipid Clinic Network score higher than 5. Coronary artery disease was myocardial infarction or angina pectoris. Results: The prevalence of FH was 0.73% (one in 137). Of participants with FH, 20% had an LDLR or APOB mutation. The prevalence of coronary artery disease among FH participants was 33%. Only 48% of subjects with FH admitted to taking cholesterol-lowering medication. The odds ratio for coronary artery disease off cholesterol-lowering medication was 13.2 (10.0–17.4) in definite/probable FH compared with non-FH subjects, after adjusting for age, gender, body mass index, hypertension, metabolic syndrome and diabetes, and smoking. The corresponding adjusted odds ratio for coronary artery disease in FH subjects on cholesterol-lowering medication was 10.3 (7.8–13.8). Conclusion: The prevalence of FH appears to be higher than commonly perceived in a general population of white Danish individuals, with at least half of affected subjects not receiving cholesterol-lowering medication. The very high risk of coronary artery disease irrespective of use of medication reflects the extent of underdiagnosis and undertreatment of FH in the community and primary care.

Overview

Integrity signals

Registry

Crossref · 10.1210/jc.2012-1563

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 1

  1. World Health Organization, 1999, Familial hypercholesterolaemia (FH)

Cited by

See all 632

Metadata

Authors
Benn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G.
Affiliations
  • University of Copenhagen (DK)
  • The University of Western Australia (AU)
  • The Copenhagen General Population Study (M.B., A.T.-H., B.G.N.), Herlev Hospital, Copenhagen University Hospital, DK-2730 Herlev, Denmark
Corresponding author
Nordestgaard, Børge G.
Venue
The Journal of Clinical Endocrinology & Metabolism
Published
2012-11-01
Volume
97
Issue
11
Pages
3956-3964
ISSN
  • 0021-972X (ISSN-L)
  • 1945-7197
OpenAlex
W1993634977
Cited by
632
References
38
Citations by year
2026: 28 · 2025: 23 · 2024: 28 · 2023: 37 · 2022: 42 · 2021: 36 · 2020: 44 · 2019: 48 · 2018: 61 · 2017: 80 · 2016: 92 · 2015: 53 · 2014: 42 · 2013: 15 · 2012: 1
FWCI
36.15
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
  • UWA Profiles and Research Repository (UWA) (submittedVersion)
Funders
  • Amgen
  • Pfizer
  • AstraZeneca
  • Sanofi
  • Sundhed og Sygdom, Det Frie Forskningsråd
  • Regeneron Pharmaceuticals
  • Gentofte Hospital
  • Herlev Hospital
  • Medical Research Council
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
familial hypercholesterolemia, prevalence, coronary artery disease, cholesterol-lowering drugs, LDLR mutations, APOB mutations, Dutch Lipid Clinic Network criteria, underdiagnosis, undertreatment, myocardial infarction, angina pectoris, Copenhagen General Population Study
MeSH terms
Aged, Anticholesteremic Agents, Coronary Artery Disease, Denmark, Female, Genotype, Humans, Hyperlipoproteinemia Type II, Lipids, Lipoproteins, Male, Middle Aged, Risk, Prevalence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. https://app.cochat.ai/papers/10.1210/jc.2012-1563
The paper
Benn, M., Watts, G. F., Tybjaerg-Hansen, A., & Nordestgaard, B. G. (2012). Familial Hypercholesterolemia in the Danish General Population: Prevalence, Coronary Artery Disease, and Cholesterol-Lowering Medication. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.2012-1563

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.